Bellerophon Therapeutics, Inc.·4

Feb 19, 5:29 PM ET

Bellerophon Therapeutics, Inc. 4

4 · Bellerophon Therapeutics, Inc. · Filed Feb 19, 2015

Insider Transaction Report

Form 4
Period: 2015-02-13
MEGLASSON MARTIN
Chief Scientific Officer
Transactions
  • Award

    Stock Option (right to buy)

    2015-02-13+1,9951,995 total
    Exercise: $12.00Exp: 2025-02-12Common Stock (1,995 underlying)
Footnotes (1)
  • [F1]This option was granted on February 13, 2015. This option vests as to 25% of the underlying shares on each one year anniversary of the date of grant.

Documents

1 file
  • 4
    a4.xmlPrimary

    4